News & AnalysisDevastation in Japan

Candidate Radiation Drugs Inch Forward

See allHide authors and affiliations

Science  25 Mar 2011:
Vol. 331, Issue 6024, pp. 1505
DOI: 10.1126/science.331.6024.1505

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Beyond potassium iodide, whose utility is limited to warding off thyroid cancer, the pharmaceutical industry has no proven drugs to ward off the devastating health effects of a large radiation exposure. Over the past 5 years, however, a few promising candidates have begun to undergo animal, and even human, testing. Still, only a few companies and academic groups are addressing this unmet need. The obvious lack of a commercial market may explain why. But some also blame the U.S. government's relative indifference toward the development of radiological countermeasures compared with biodefense.